These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 30446652)

  • 41. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
    Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained Response with Dose-reduced Selpercatinib in a Pediatric Patient with Metastatic NCOA4-RET Fusion Papillary Thyroid Carcinoma.
    Suydam AC; Bach A; Markovina S; Grigsby P; Sprague J; Armstrong AE
    J Pediatr Hematol Oncol; 2023 Nov; 45(8):e984-e987. PubMed ID: 37565829
    [TBL] [Abstract][Full Text] [Related]  

  • 44. KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer.
    Qian Y; Chai S; Liang Z; Wang Y; Zhou Y; Xu X; Zhang C; Zhang M; Si J; Huang F; Huang Z; Hong W; Wang K
    Mol Cancer; 2014 Jul; 13():176. PubMed ID: 25047660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.
    Skálová A; Vanecek T; Uro-Coste E; Bishop JA; Weinreb I; Thompson LDR; de Sanctis S; Schiavo-Lena M; Laco J; Badoual C; Santana Conceiçao T; Ptáková N; Baněčkova M; Miesbauerová M; Michal M
    Am J Surg Pathol; 2018 Nov; 42(11):1445-1455. PubMed ID: 30045065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
    Prazeres H; Couto JP; Rodrigues F; Vinagre J; Torres J; Trovisco V; Martins TC; Sobrinho-Simões M; Soares P
    Endocr Relat Cancer; 2011 Aug; 18(4):401-12. PubMed ID: 21551259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
    Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
    Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RET fusion as a novel driver of medullary thyroid carcinoma.
    Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ
    J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NRG1 fusions in breast cancer.
    Howarth KD; Mirza T; Cooke SL; Chin SF; Pole JC; Turro E; Eldridge MD; Garcia RM; Rueda OM; Boursnell C; Abraham JE; Caldas C; Edwards PAW
    Breast Cancer Res; 2021 Jan; 23(1):3. PubMed ID: 33413557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
    Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
    J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
    Spanheimer PM; Cyr AR; Gillum MP; Woodfield GW; Askeland RW; Weigel RJ
    Ann Surg; 2014 Apr; 259(4):793-9. PubMed ID: 24045439
    [TBL] [Abstract][Full Text] [Related]  

  • 55. S100 and CD34 positive spindle cell tumor with prominent perivascular hyalinization and a novel NCOA4-RET fusion.
    Michal M; Ptáková N; Martínek P; Gatalica Z; Kazakov DV; Michalová K; Stoláriková L; Švajdler M; Michal M
    Genes Chromosomes Cancer; 2019 Sep; 58(9):680-685. PubMed ID: 30938880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.
    Guan L; Li Z; Xie F; Pang Y; Zhang C; Tang H; Zhang H; Chen C; Zhan Y; Zhao T; Jiang H; Jia X; Wang Y; Lu Y
    J Exp Clin Cancer Res; 2020 Mar; 39(1):53. PubMed ID: 32293499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RET fusion gene: translation to personalized lung cancer therapy.
    Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K
    Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cabozantinib: Mechanism of action, efficacy and indications].
    Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
    Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
    Gainor JF; Shaw AT
    Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.